News Daily News FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention Shelley Wood June 01, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020
News Daily News FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients Todd Neale October 12, 2018